Find your path to Ros
575 people in our graph share verified history with Ros — schools, employers, funds. One of them is your warm intro.
Chris BischoffunlockedRos: together at INSEAD (2000–2001)
Ros: together at INSEAD
×4Ros: together at KPMG
×3Ros: together at University of Cambridge
About
Ros Deegan is CEO of OMass Therapeutics and a board member of the BioIndustry Association, with 20 years of experience across biotech, pharma, and consulting in Europe and the US. Her background includes business development and commercial transactions for companies such as Bicycle Therapeutics, Trevena, and GSK, along with senior-level work in strategy, finance, operations, and other functions at early-stage companies. She holds an MBA from INSEAD and an undergraduate degree from Cambridge.
Executive at Omass
Intro paths
→
In turn, Ros can intro founders to Omass's investors below.
Omass's investors · 5
Co-founders at Omass
PD
Professor Dame Carol RobinsonFounder and Chair of Scientific Advisory Board
IL
Idlir LikoFounder
JH
Jonathan HopperVice President, Platforms and Founder
HY
Hsin Yung (Jason) YenFounder
Experience
- BioIndustry AssociationBoard Membercurrent2024 — present
- OMass TherapeuticsCEOcurrent2019 — presentGreater Oxford Area
- @10 Downing StreetUK Prime Minister's 2024 Business Council2024
- Bicycle Therapeutics, Inc.President and CBO2016 — 2019Cambridge, Ma
- ConsultantStrategy Consultant2015 — 2016
- Trevena, Inc.SVP Business Development and Operations2008 — 2015King of Prussia, PA
- GSKDirector2001 — 2008
- KPMGSenior Consultant1998 — 2000
- adelphiGraduate Trainee1996 — 1998
Skills & more
Board LevelBoard GovernanceBoard OperationDrug Development20Drug Discovery2Biotechnology14Lifesciences2Pharmacology2Clinical Trials2Clinical Development5Medicinal ChemistryBiopharmaceuticals2
+10 more
OncologyCross-functional Team LeadershipImmunologyCommercializationLife SciencesBusiness DevelopmentCTMSPharmaceutical IndustryCROStrategyLanguages French
- Member of LifeScience ORG — LifeScience ORG
From Ros's professional profile.
Frequently asked questions
- Who is Ros Deegan?
- Ros Deegan is CEO of OMass Therapeutics and a board member of the BioIndustry Association, with 20 years of experience across biotech, pharma, and consulting in Europe and the US. Her background includes business development and commercial transactions for companies such as Bicycle Therapeutics, Trevena, and GSK, along with senior-level work in strategy, finance, operations, and other functions at early-stage companies. She holds an MBA from INSEAD and an undergraduate degree from Cambridge.
- Where did Ros Deegan go to school?
- Ros Deegan studied at INSEAD (Master of Business Administration (MBA), Business Administration and Management); University of Cambridge (Master of Philosophy (MPhil), Department of Medicine); University of Cambridge (BA, Natural Sciences).
Same school
Also attended INSEAD1,343
Alexandre ProtCo-founder & CEO of QontoSteve AnaviCo-founder & President of QontoPatrick ClaessenPartner at Cottonwood Technology FundChris BischoffInvestment Team at General CatalystJan HammerInvestor at Index VenturesSandra SchwarzerInvestor at Index Ventures
+ 1,337 more
Also attended University of Cambridge1,600
Stewart ButterfieldCo-founder of Slack and FlickrDemis HassabisCo-founder & CEO of Google DeepMindNiko BonatsosFounder and Managing Partner of VerdictGeorgia StevensonInvestor at Index VenturesHannah SealInvestor at Index VenturesLeah von SiemensPartner at Manta Ray Ventures
+ 1,594 more
Shared employers
Also worked at OMass Therapeutics6
Also worked at @10 Downing Street14
Tom HulmeInvestor at GV (Google Ventures)Nick CleggGeneral Partner at Hiro CapitalTom PageHead of Investor Relations at Cambridge Innovation CapitalAbi WyeNetwork Director at Future Planet CapitalMatt CliffordCofounder and Chair at Entrepreneur FirstTom ShinnerPartner and COO at Entrepreneur First
+ 8 more
Also worked at Trevena, Inc.6
Jake NunnPartner at SR One Capital ManagementScott BraunsteinVice-Chairman of the Board and Director at atai Life SciencesJohn P. HamillExecutive Officer at ApreaMark CorriganExecutive Officer at Tremeau PharmaceuticalsJohn M. LimongelliChief Financial Officer and Chief Legal Officer at ImvaxDavid SoergelExecutive Vice President and Chief Medical Officer at Madrigal
